Evidence map›Paper›PMID 40293565›Full record

ArticleMolecular biology reports2025

Role of traditional and new biomarkers in the assessment of chronic kidney diseases: a comprehensive analysis of the biochemical, molecular and clinical dimensions.

Arumugam Suresh, Natarajan Muninathan, Shobana Sampath, Sandhanasamy Devanesan, Mohamad S AlSalhi, D Manoj

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Arumugam SureshCentral Research Laboratory, Meenakshi Medical College Hospital and Research Institute, Meenakshi Academy of Higher Education and Research, Kanchipuram, Tamil Nadu, India.
Natarajan MuninathanCentral Research Laboratory, Meenakshi Medical College Hospital and Research Institute, Meenakshi Academy of Higher Education and Research, Kanchipuram, Tamil Nadu, India. muninathanpappaiya@gmail.com.
Shobana SampathDepartment of Biotechnology, Vel Tech Rangarajan Dr Sagunthala R&D Institute of Science and Technology, Chennai, Tamil Nadu, 600062, India. swtshoba@gmail.com.
Sandhanasamy DevanesanBioproducts Research Chair, Department of Zoology, College of Science, King Saud University, Riyadh, Saudi Arabia.
Mohamad S AlSalhiDepartment of Physics and Astronomy, College of Science, King Saud University, P. O. Box 2455, Riyadh, 11451, Saudi Arabia.
D ManojDepartment of Physics and Astronomy, College of Science, King Saud University, P. O. Box 2455, Riyadh, 11451, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKidney function is necessary for the diagnosis and treatment of renal diseases. Traditional biomarkers like creatinine have limitations due to their susceptibility to interference and fluctuation. This study's objective is to test and compare the efficacy of conventional and innovative biomarkers in evaluating kidney function and disease.

methodsWe looked at creatinine, cystatin C, parathyroid hormone (PTH), electrolytes, interleukin-6 (IL-6), C-reactive protein (CRP), the APA I gene, and kidney injury molecule-1 (KIM-1). The present study focused on the stability, sensitivity, and specificity of biomarkers using a combination of traditional and innovative analytical techniques.

resultsPresent results showed that creatinine, although commonly used as a measure, frequently overestimates renal function as a result of chromogenic interference. On the other hand, cystatin C showed better sensitivity and was less reliant on influences outside the kidneys. Kidney biomarkers, such as KIM-1, exhibit the potential for identifying acute kidney injury at an early stage. Furthermore, there was a positive correlation between increased levels of CRP and PTH and the progression of kidney disease to more advanced stages.

conclusionThis study emphasizes the importance of combining traditional and new biomarkers to improve the accuracy of diagnosing and managing kidney illness. The more effective use of biomarkers will result in improved patient outcomes.

Indexed as

BiomarkersRenal Insufficiency, ChronicAdultAgedC-Reactive ProteinCreatinineCystatin CFemaleHepatitis A Virus Cellular Receptor 1HumansInterleukin-6Kidney Function TestsMaleMiddle AgedParathyroid HormoneSensitivity and SpecificityBiomarkersC-Reactive ProteinCreatinineCystatin CHAVCR1 protein, humanHepatitis A Virus Cellular Receptor 1Interleukin-6Parathyroid HormoneCreatinineCystatin CElectrolytesKidney injury molecule-1 (KIM-1)Parathyroid hormone (PTH)

Identifiers

PMID40293565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.